0 (0%)		09-16 07:38
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	72.71	1-year :	74.86
Resists	First :	62.25	Second :	64.09
Pivot price	61.62
Supports	First :	59.27	Second :	49.31
MAs	MA(5) :	61.04	MA(20) :	61.83
	MA(100) :	56.46	MA(250) :	51.43
MACD	MACD :	0.2	Signal :	0.4
%K %D	K(14,3) :	26.9	D(3) :	24.9
RSI	RSI(14): 48.8
52-week	High :	64.09	Low :	38.25

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PTH ] has closed above bottom band by 29.9%. Bollinger Bands are 25.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	61.39 - 61.74	61.74 - 62.06
Low:	59.6 - 59.98	59.98 - 60.33
Close:	60.25 - 60.87	60.87 - 61.43

Wed, 16 Sep 2026
The Alkaline Trap: Severe Calcium-Alkali Syndrome Secondary to Chronic Calcium Carbonate Ingestion - Cureus

Thu, 10 Sep 2026
Spatial control of parathyroid hormone receptor-1 signaling dictates ligand-specific biological outcomes - Nature

Fri, 12 Jun 2026
One-Year Canvuparatide Data Support Once-Weekly PTH Replacement Approach in Chronic Hypoparathyroidism - BioPharm International

Fri, 12 Jun 2026
TransCon PTH Shows 82% Response Rate in 5-Year Hypoparathyroidism Trial - The Clinical Trial Vanguard

Thu, 11 Jun 2026
Emerging Therapies in Hypoparathyroidism and Renal Outcomes of PTH Replacement - HCPLive

Tue, 12 May 2026
Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial - AstraZeneca

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.